This conference will address innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials.
Conference Website
 | Aadi Bioscience @aadibio | 100 |
 | Aadi Bioscience @aadibio_pr | 15 |
Last 7 days by SymplurRank updated .
 | @fireflyann [REDACTED USER] [REDACTED USER] @MDAndersonNews Hi.. I'm a little confused by the trial Listing as title says "kras wild".. but inclusions for KRAS. I do see the KRAS G12V arm. Might there be slides/poster available for pts? @KRASKickers did share this link https://t.co/RHBQE93PkG |
 | @HemeoncF @StephenVLiu @AlexSpiraMDPhD @AACR Any good luck with G12 D? Have a metastatic colon with G12D. Any trial suggestion? |
 | @ApexOnco Nested Therapeutics' lead asset NST-628, described as a pan-RAF/MEK "non-degrading molecular glue", just went into phase 1. Had preclinical data at #Targets23 https://t.co/iWwmTUC3gw |
 | @Quantumup1 Piper Sandler  $TNGX OW/$18
$TNGX' MTA-cooperative PRMT5 inhibitor portfolio is well positioned w/in precision onc.
PS sees initial clinical data from MRTX1719/ AMG 193 as establishing *unambiguous clinical PoC4class; sees TNG908/TNG462 as pot FiC/BiC opp.
$BMY $MRTX $AMGN $IDYA https://t.co/iW2UZJ0su6 |
 | @ValverdeRB @ElizSMcKenna [REDACTED USER] @CD_AACR [REDACTED USER] way follow |
 | @AACRFoundation A recent conference cosponsored by @AACR highlighted basic and clinical research into targeted cancer therapies. Learn more on the #AACRBlog: https://t.co/l7B4pxCP85 #Targets23 https://t.co/EUnodJ1jlq |
 | @genprex @Bell2BellBuzz’s latest podcast features Dr. Mark Berger, Genprex's CMO. Dr. Berger provided valuable insights into recent groundbreaking achievements, particularly focusing on the promising data presented at the #Targets23 conference. Listen here: https://t.co/ti97RoDTnz $GNPX |
 | @Molly20186 RT @Quantumup1: OPY  $IDYA $40was$35/OP
after Ideaya recently reported a substantial pipeline update that incrementally derisked the story… |
 | @Ruven27 RT @Quantumup1: OPY $IDYA $40was$35/OP
after Ideaya recently reported a substantial pipeline update that incrementally derisked the story… |
| @Quantumup1 OPY $IDYA $40was$35/OP
after Ideaya recently reported a substantial pipeline update that incrementally derisked the story; darovasertib + crizotonib combo still looks head/shoulders >anything out there for UM.
+'s IDE397 continues2 demonstrate clear single-agent activity.
$amgn |
 | @GuileyThy RT @ElizSMcKenna: Is p53 the next "undruggable" target to become druggable in cancer? For more, read this recent @CD_AACR paper by Keelan G… |
#Targets23 content from Twitter.
